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Chronic infection with the hepatitis C virus (HCV) is a major cause of liver 
disease worldwide and is also responsible for extrahepatic manifestations (EHM) 
involving many different organs and apparatus: skin, salivary glands, eyes, 
thyroid, kidneys, peripheral and central nervous system, and immune system. 
Mixed cryoglobulinemia is the most frequent, best known and strictly HCV-
associated EHM. A significant association between HCV and B-cell Non-Hodgkin-
Lymphoma is reported although the incidence of lymphoma among HCV-infected 
patients overall remains low. HCV-infected patients have increased rates of insulin 
resistance, diabetes, and atherosclerosis, which may lead to increased cardiovas-
cular disorders. The mechanisms causing the extrahepatic effects of HCV infec-
tion are likely multifactorial and may include endocrine effects, HCV replication 
in extrahepatic cells, or a heightened immune reaction with systemic effects. 
Because of this associations, it is suggested testing for HCV infection the patients 
with a clinical condition described as linked to hepatitis C. Conversely, patients 
diagnosed with HCV infection should have evaluation for a possible EHM. EHM 
of HCV can be considered an established indication for antiviral treatment with 
direct acting antivirals, even in the absence of overt liver disease. Successful eradi-
cation of HCV can improve and in some cases cure EHM of HCV. B cell depleting 
agents may be considered to be the best biological target option for patients with 
more severe EHM in combination with the antivirals.
Keywords: HCV, chronic hepatitis C, cryoglobulinemia, B-cell lymphoma, thyroid 
dysfunction, type 2 diabetes, Sjögren’s syndrome, porphyria cutanea tarda, lichen 
planus, glomerulonephritis, neuropathy, polyarthritis, extrahepatic manifestations
1. Introduction
Persistent infection with hepatitis C virus (HCV) is a leading cause of chronic 
liver disease, resulting in about 400000 deaths per year. The estimated global HCV 
prevalence is 1.0%, corresponding to 71 million individuals. Antiviral medicines 
can cure more than 95% of persons with hepatitis C infection, thereby reducing the 
risk of death from cirrhosis and liver cancer, but access to diagnosis and treatment is 
low. There is currently no effective vaccine against hepatitis C; however, research in 
this area is ongoing [1].
However, these data are underestimated do not taking into account the extrahe-
patic aspects that make this infection a systemic disease. Early after its discovery, it 
was shown that HCV is not only hepatotropic but also lymphotropic. It was also shown 
that several extrahepatic manifestations (EHM) can complicate HCV infection [2–4].
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Moreover, chronic HCV infection has been associated with numerous EHM and 
diseases, although a direct link is often difficult to establish.
Association should not be confused with causality. The association merely suggests 
a hypothesis, such as a common cause, but does not offer proof [5].
A causal relationship is easily acceptable if the strength of association is hight. 
Furthermore, according to the criterion of plausibility, the association ought to be 
biologically plausible.
The EHM described as linked to HCV hepatitis are numerous:
Mixed cryoglobulinemia (MC), sicca syndrome (SS), Non-Hodgkin Lymphoma 
(NHL), serum monoclonal gammopathy, thyroid disease, type 2 diabetes mellitus 
and glucose intolerance, many autoimmune disorders, renal disease, rheumatologic, 
neurological, cardiovascular and dermatological disorders [6] (Figure 1).
Here are described the most clinical important and best studied of these 
pathological conditions.
2. Biological plausibility and pathophysiology
The pathophysiology of EHM of HCV hepatitis is only in part understood and 
for some of them unexplained.
The mechanisms causing the extrahepatic effects of HCV infection are likely 
multifactorial and may include endocrine effects, HCV replication in extrahepatic 
cells, or a heightened immune reaction with systemic effects.
Due to the fact that HCV has been shown to infect both hepatocytes and lym-
phocytes, lymphoproliferative diseases such as lymphoma and MC are most closely 
linked to hepatitis C infection. These conditions are the most studied from the point 
of view of their pathophysiology. The primary mechanism of injury in cryoglobuli-
nemia is a vasculitis triggered by immune complex deposition.
HCV has been shown to be a lymphotropic virus and associated with several 
lymphoproliferative disorders, including monoclonal gammopathies in addition to 
Figure 1. 
The spectrum of extrahepatic manifestations of HCV [6].
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MC and B-cell NHL. HCV infection of lymphocytes could play a direct role in cel-
lular transformation, specifically in de novo large B-cell lymphoma. HCV infection 
of two B-cell lines can produce mutations in tumor suppressor and proto-oncogenes 
which were identified in HCV-associated B-cell lymphomas.
Two particulars although not mutually exclusive models of infection-driven 
malignant transformation were described.
Direct lymphocyte transformation by lymphotropic transforming viruses 
(Epstein–Barr virus, human herpesvirus, and human T-lymphotropic virus type) 
expressing viral oncogenes has been reported. A model of lymphocyte transforma-
tion finally leading to clonal expansion as an indirect mechanism of pathogenesis 
has been proposed. Sustained stimulation of lymphocyte receptors by viral anti-
gens, viral replication in B-cells, and damage of B-cells have been also proposed as 
mechanisms of pathogenesis.
Expression of HCV viral proteins in B-cells of HCV-infected patients upregulates 
B-cell receptor signaling. Pro-inflammatory cytokines, such as the interleukins  
(IL-6, IL-17 and IL-10) and transforming growth factor-beta have also been 
reported to contribute to aberrant B-cell proliferation.
Glomerular injury in HCV-related glomerulonephritis is primary induced by a 
deposition of circulating immunocomplexes containing anti-HCV antibodies, HCV 
antigens and complement factors. Formation and deposition of such immunocom-
plexes occurs also in absence of cryoglobulins. Formation of glomerular antibodies 
is a further possible mechanism of HCV-related glomerular injury.
Peripheral nerves of patients with HCV-related peripheral neuropathy may show 
vasculitic changes involving the vasa nervorum, giving a possible explanation of 
nerve damage.
Studies have shown that dysthyroidism is mediated by immunological mecha-
nisms rather than by direct HCV infection. The pathogenesis may involve changes 
in self-antigen expression and sustained stimulation of the immune system by 
HCV, bystander activation of autoreactive T-cells by cytokine release, infection of 
the lymphatic cells, chromosomal aberrations and abnormal expression of major 
histocompatibility complex class II molecules by thyrocytes, or cross-reactivity 
between viral antigens and thyroidal antigens.
Primary causation of dermatological EHM (apart the cryoglobulinaemic ones) 
results from direct infection of HCV in the skin, lymphocytes, dendritic antigen-
presenting cells, and blood vessels. Secondary causation occurs when HCV infec-
tion manifests in the skin due to epiphenomena resulting from the disruption of 
immune responses [2–4, 6, 7].
The most common extrahepatic findings with which the relationship to HCV 
infection is more strongly established are cryoglobulinemia, autoimmune disorders 
(including autoantibodies and SS), porphyria cutanea tarda (PCT), and lichen 
planus (LP). There also appears to be a clear association with B-cell NHL (particu-
larly in patients with underlying cryoglobulinemia), but the incidence of lymphoma 
among HCV-infected patients overall remains low.
3. Mixed cryoglobulinemia
MC is the most frequent, best known and strictly HCV-associated EHM (about 
90% of MC patients tested positive for HCV antibodies in some studies) [7, 8].
MC may be defined a both autoimmune and B-lymphoproliferative disorder 
(LPD) that may evolve to a frank malignancy in about 8–10% of cases [9].
The definition of MC refers to the presence of serum Igs that reversibly pre-
cipitate at low temperatures (<37°C) and are represented by circulating immune 
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complex typically consisting of an IgM rheumatoid factor (mono-oligoclonal 
in type II MC, or polyclonal in type III MC) and polyclonal Ig (most frequently 
IgG) including anti-HCV antibodies. MC has been generally reported, at least 
subclinical, in the majority of HCV patients, even if data may widely vary in 
different geographical areas (from 20 to >50%). Only a minority of MC patients 
(5 to >30%) shows a symptomatic MC or MC syndrome (usually women aged 
more than 50 years), but even asymptomatic patients might develop MC in the 
future [10].
Factors that seem to favor the development of MC are female sex, increasing age, 
alcohol consumption (> 50 g/day), advanced liver fibrosis and steatosis.
The clinical manifestations of MC are secondary to a systemic vasculitis charac-
terized by the deposition of cryoglobulins in the vessels and can be classified as one 
of the circulating immune complexes mediated systemic vasculitis involving small 
and medium-sized blood vessels.
The classic syndrome of MC consists in the triad of purpura, fatigue and arthral-
gia, but the various involvement of different organs and tissues (mainly skin, joints, 
renal, peripheral nerves) leads to variable clinical presentation and evolution.
Palpable purpura (leukocytoclastic vasculitis) and petechiae most often affects 
the legs (Figure 2).
Papules, ulcers, and livedo can also occur and can affect any skin site.
Reynaud Syndrome can be present, with or without digital gangrene, in about 
one third of patients.
Figure 2. 
Cutaneous manifestation of mixed cryoglobulinemia (see text).
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Common manifestations of MC are arthralgias (polyarthralgia, but relatively 
rare is arthritis), renal disease, usually membranoproliferative glomerulonephritis 
(MPGN), and neurologic disease.
MPGN is characterized in most cases by proteinuria, mild haematuria and 
mild renal insufficiency. In the worst cases, a severe involvement of the kidney is 
observed (15% of cases).
The peripheral neuropathy including mixed neuropathies (prevalently sensitive, 
axonal) is common in MC (80–90% of cases), and also in HCV without MC (see 
below 9.).
HCV-related peripheral neuropathy is characterized by numbness, burning skin 
and pruritus.
Central nervous system involvement in patients with HCV-positive MC is rare 
(see below 9).
4. Sicca syndrome (secondary SjÖgren syndrome)
SjÖgren syndrome is described as a chronic, slowly progressive autoimmune 
disease characterized by lymphocytic infiltration of the exocrine glands and 
B-lymphocyte reactivity resulting in xerostomia and dry eyes. SS, to be differenti-
ated from the primary SjÖgren Syndrome, occurs in MC and also in HCV patients 
without MC [2–4]. In most instances the typical serological and histopathologic 
findings of SjÖgren Syndrome are lacking. SS is more frequently reported in type II 
than in type III MC [2, 4].
Some studies showed an association between MC in HCV infected patients and 
severe liver damage [11].
However, discordant data exist. It is common clinical experience, including our 
own, to find patients with symptomatic HCV-related MC and a mild or moderate 
liver disease and conversely patients with the most severe form of chronic hepatitis 
C (advanced fibrosis, compensated and decompensated cirrhosis, hepatocellular 
carcinoma) without any symptom of MC (even when laboratory testing positive 
for MC).
5. Non-Hodgkin lymphoma and other hematological disorders
5.1 Non-Hodgkin lymphoma
The very close association between MC and HCV infection leads to the hypothesis 
that HCV may be involved in the pathogenesis of lymphoma as well.
A significant association between HCV and B-cell NHL was reported and 
confirmed in the large majority of studies [12].
This association involves different histopathological types of B-cell NHL, the 
most strictly associated being the lymphoplasmacytic, marginal zone and diffuse 
large B-cell lymphoma.
Some discordant data suggested the contribution of genetic factors and the 
incidence of lymphoma among HCV-infected patients overall remains low.
In an observational, prospective, multicenter, case–control study, the prevalence 
of HCV-antibodies was found of 0.16 among NHL and of 0.085 among controls and 
non-lymphoid malignancies patients [13].
Although the difference was statistically significant (P < 0.001), the odds 
ratio was 2.049 and its confidence intervals included the equality. NHL features 
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among HCV-positive and HCV-negative patients observed in this study are 
reported in the Table 1.
5.2 Serum monoclonal gammopathy and thrombocytopenia
A serum monoclonal gammopathy (MG), more frequently type IgMk and diag-
nosed as MG of uncertain significance (MGUS), was frequently observed in HCV 
patients, in most cases associated with a 2a/c genotype of the virus.
Available data suggest that HCV-related LPD are the result of multiple and 
cooperating mechanisms and events belonging to three principal categories: an 
important and sustained activation of the B-cell compartment; an inhibition of 
B-cell apoptosis; genetic/epigenetic and environmental factors (see also above 2.).
Thrombocytopenia is often observed in patients with chronic HCV hepa-
titis and sometimes it is disproportionally severe with respect of the stage of 
fibrosis-cirrhosis.
It is possible recognize as causal factors of thrombocytopenia in HCV chronic 
hepatitis the following: decrease of hepatic thrombopoietin, direct cytopathic 
involvement of HCV on megakaryocytes, production of platelets-associated 
immunoglobulins, hypersplenism.
6. Endocrine pathology and hepatitis C virus infection
6.1 Thyroid disease
The prevalence of thyroid disorders is generally high in HCV-positive 
patients and most frequently represented by antithyroid peroxidase antibodies 











Extranodal inv. (0.593) 30 0.625 (0.488–0.762) 148 0.587 (0.526–0.648)
Marrow inv. (0.283) 16 0.333 (0.200–0.466) 69 0.274 (0.219–0.329)
Stomach inv. (0.067) 2 0.042a 18 0.071 (0.039–0.103)
Liver inv. (0.030) 4 0.083 (0.005–0.161) 5 0.020 (0.003–0.037)
Cryoglobulinis (0.033) 3 0.063a 7 0.028 (0.026–0.030)
Age to 20 (0.007) 0 0 2 0.008a
Age 21–40 (0.090) 2 0.042a 25 0.099 (0.062–0.136)
Age 41–60 (0.300) 12 0.250 (0.128–0.372) 78 0.310 (0.253–0.367)
Age > 60 (0.603) 34 0.708 (0.579–0.837) 147 0.583 (0.522–0.643)
WF A, B, Cb (0.286) 14 0.304 (0.071–0.437) 70 0.283 (0.227–0.339)
WF D, E, Fb (0.248) 10 0.217 (0.098–0.336) 63 0.255 (0.201–0.309)
WF G, H, I, Jb (0.464) 22 0.478 (0.334–0.622) 114 0.462 (0.400–0.524)
MALT (0.053) 3 0.062a 13 0.052 (0.022–0.088)
aLower confidence limit below.
bWF classification is available for 293.
Table 1. 
NHL features among HCV-positive and HCV-negative patients [13].
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in female subjects. Hypothyroidism has been frequently observed, especially  
in HCV MC, and an association with papillary thyroid carcinoma was also  
shown [14].
6.2 Type 2 diabetes mellitus and glucose intolerance
Several studies showed that HCV (especially genotype 3) could lead to the 
development of type 2 diabetes mellitus, possibly as a result of HCV-induced meta-
bolic disturbances. However, discordant data exist. Insulin resistance was observed 
in 30–70% of HCV patients [3, 15].
The cause of the association of HCV with diabetes is unknown. In addition, 
the magnitude of the association may be overestimated because patients with 
diabetes have more parenteral exposures than the general population, placing them 
at increased risk for transmission of blood transmitted viruses. Furthermore, not 
all studies controlled for the presence of cirrhosis, which may be associated with 
impaired glucose tolerance.
7. Autoimmune and rheumatologic disorders
7.1 Autoantibodies
A number of autoimmune disorders have been associated with chronic HCV 
infection, including subclinical autoantibody formation, autoimmune thyroid 
disease, sialadenitis/SS, and autoimmune thrombocytopenic purpura.
Autoantibodies are common in patients with chronic HCV infection. 
Antinuclear antibodies, antibodies directed against the Fc portion of IgG (rheuma-
toid factor), anticardiolipin antibodies, smooth muscle antibodies, or antithyroid 
antibodies are detected in 40 to 65 percent of patients. While antibodies are often 
present in low titres, do not appear to influence the presentation or course of the 
infection.
Nevertheless, the presence of autoantibodies may result in diagnostic 
difficulties.
For example, an HCV-infected patient with arthralgias, arthritis, and rheu-
matoid factor positivity may be misdiagnosed initially as having rheumatoid 
arthritis. In this setting, testing for other rheumatoid-arthritis-associated 
autoantibodies that are observed infrequently in patients with HCV infec-
tion, such as anti-citrullinated peptide antibodies (anti-CCP), may be helpful 
diagnostically.
In other cases, a difficult differential diagnosis between hepatitis C and auto-
immune hepatitis can rise. In these cases, the liver biopsy findings are decisive. In 
rare cases the two disease coexist in the same patient.
Making a precise diagnosis is crucial because the treatment is completely 
different.
7.2 Rheumatologic disorders
Polyarthralgia is the most common rheumatologic symptom described in 
HCV-infected patients. HCV arthritis could be part of the MC or be independent. 
HCV-associated oligoarticular or polyarticular non-erosive arthritis can clinically 
mimic rheumatoid arthritis, although anti-CCP antibodies and erosive joint changes 




Typical manifestation of lichen planus of the volar distal forearm and wrist in a hepatitis C patient (see text).
8. Renal disease
Several renal manifestations have been associated with HCV infection, the most 
common being MPGN. HCV-associated membranous or proliferative glomerulone-
phritis or focal segmental glomerulosclerosis have been also described. The strongest 
association was reported for cryoglobulinaemic MPGN. Microhaematuria and 
proteinuria are the most frequent clinical findings of MPGN. The presence of a renal 
involvement is one of the worst prognostic indices in the natural history of MC [16].
9. Neurological disorders
Peripheral neuropathy: see above, in the context of MC. Less frequently, 
peripheral neuropathy can be present without MC. Peripheral neuropathy can be 
sensory or sensorimotor.
Symptoms of fatigue and deficits in concentration and working memory are 
commonly reported in patients with chronic HCV infection. Some studies have 
suggested neurocognitive impairments associated with HCV, even after controlling 
for other comorbid conditions, such as substance abuse, affective disorders, and 
cirrhosis. Functional imaging studies have also identified metabolic changes in the 
central nervous system in the setting of HCV infection (not ascribable to hepatic 
encephalopathy) [3].
10. Dermatological manifestations
Apart the dermatological manifestations of MC (see above 3.) the are other 
dermatological conditions associated with HCV infection deserving to be discussed.
10.1 Lichen planus
Cutaneous LP is characterized by flat-topped, pink to violaceous, pru-
ritic papules with a potentially generalized distribution. The papules appear 
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polygonal-shaped, translucent under incident light. They are 2–4 mm in diameter, 
with irregular margins and a hard-elastic consistency (Figure 3). LP can also 
involve mucus membranes, hair, and nails.
HCV infection has been reported frequently among patients with LP. In some 
studies, the prevalence of anti-HCV antibodies in patients with LP ranges from 
10 to 40%.
Systematic reviews have reported that patients with oral LP planus are approxi-
mately two to six times more likely to have reactive anti-HCV antibodies compared 
with controls, although there is substantial geographical heterogeneity to the 
findings.
LP can be seen in patients with a variety of liver diseases, particularly advanced 
liver disease.
There is evidence of a genetic risk for HCV-associated LP. The most commonly 
used drugs in cutaneous LP are topical and systemic corticosteroids, for their 
immunosuppressive and anti-inflammatory effects [4, 17, 18].
10.2 Porphyria cutanea tarda
PCT is a disease caused by reduced activity of the enzyme uroporphyrinogen 
decarboxylase (UROD), causing the subsequent build-up of uroporphyrinogen in 
the blood and urine. PCT has both sporadic and inherited (autosomal dominant) 
forms that are indistinguishable clinically. A strong association between the spo-
radic form of PCT and HCV infection has been demonstrated in multiple studies 
(an overall prevalence of HCV of 50%). However, there was marked geographic 
variability; lowest prevalence rates (20 to 30%) were observed in reports from 
Australia, the Czech Republic, and France, while the highest rates (71 to 85%) were 
observed in Japan, Italy, and Spain. The prevalence in North America was 66%.
A central factor in the geographic variability appeared to be the baseline rates of 
HCV infection in the general population.
The skin and the liver are the two main sites affected in sporadic PCT. Skin 
disease is characterized by photosensitivity and skin fragility, with which exposure 
Figure 4. 
Typical cutaneous manifestations of porphyria cutanea tarda (see text).
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to the sun and/or minor trauma can lead to skin erythema and the development of 
vesicles and bullae that may become haemorrhagic.
Hyperpigmentation, hypopigmentation, hirsutism, and sclerodermatous 
changes may develop with the passage of time (Figure 4).
Chronic liver disease is common in sporadic PCT. Liver biopsy shows a wide 
range of changes, including steatosis, mild to severe inflammation, hepatic fibrosis, 
and cirrhosis. Environmental triggers are thought to be necessary to provoke an 
attack of PCT. Possible triggers of PCT include polyhalogenated hydrocarbons 
(such as hexachlorobenzene), oestrogens, but above all, iron overload and alcoholic 
beverages. The diagnosis of PCT is typically suspected on clinical grounds and is 
confirmed by the demonstration of markedly elevated urine uroporphyrin levels. 
The diagnosis can also be made directly by measuring hepatic UROD activity. All 
patients with PCT should be tested for HCV infection, as well as other potential 
disease associations, including HIV infection, iron overload, and hemochromatosis 
(with HFE mutation testing). Careful history of alcohol intake and testing of heavy 
alcohol intake markers are fundamental.
Management of PCT in patients with HCV infection includes avoiding precipi-
tating factors (such as sun, alcohol, oestrogens, and polyhalogenated hydrocar-
bons), treating an underlying iron overload state, if present, and treating HCV 
infection.
PCT often, but not always, improves with clearance of HCV viremia. The cur-
rently used pharmacological protocol for PCT include the administration of a half 
tablet of chloroquine (125 mg) twice a week [19, 20].
11. Cardiovascular and respiratory diseases
Although data from individual cohorts have not been consistent, evidence 
overall suggests that chronic HCV infection is associated with adverse cardiovascu-
lar diseases and outcomes: dilated cardiomyopathy, hypertrophic cardiomyopathy 
and arrhythmogenic right ventricular cardiomyopathy, myocarditis, and aortic 
atherosclerosis. These associations are still object of debate. Because cardiovascular 
diseases are common and multifactorial, it is difficult to determine whether HCV is 
a major contributing factor in an individual patient [3].
Idiopathic pulmonary fibrosis is a serious condition described in association 
with HCV infection.
12. Clinical implications and laboratory tests
Because of the associations, it is suggested testing for HCV infection in patients 
with clinical condition described above and other suspected to be linked to HCV. 
Anti-HCV antibodies (an inexpensive test) must be checked and if positive, quanti-
tative HCV-RNA, genotype and complete workup of hepatitis C performed.
Conversely, patients diagnosed with chronic HCV infection should have evalua-
tion for EHM at the initial visit and routinely during follow-up. History of an HCV-
infected patient should cover rheumatologic symptoms (e.g., arthritis/arthralgias, 
dry eyes or mouth) and the physical exam should include a skin exam to evaluate 
for findings of cryoglobulinemia, PCT, and other associated dermatologic features. 
Superficial lymph node sites must be checked. Abdominal ultrasound is part of the 
HCV patient evaluation. It is in addiction necessary to perform a chest x-ray with 
particular attention to the mediastinum.
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Laboratory testing should include a complete blood count, an assessment of 
renal function, evaluation for proteinuria and haematuria, and thyroid function 
tests. Cryoglobulins and complement levels should be checked if there is evidence 
of renal disease or other compatible clinical findings. Testing for other EHM should 
be guided by symptoms or specific physical findings.
Mild serum amylase elevation is a common finding in HCV patients generally 
without any pancreatic involvement clinically detectable.
13. Treatment of extrahepatic manifestations of HCV infection
13.1 Antiviral treatment
The armamentarium against HCV has been expanded with the availability of 
molecules able to directly target non-structural proteins that play a key role in HCV 
replication. These agents, orally administrated for a relatively short period of time 
(2–3 months) have been called direct acting antivirals (DAA) and target some of the 
main molecular components of HCV, including NS3/4A protease (first and second-
generation protease inhibitors), NS5B polymerase (nucleoside and non-nucleoside 
analogues) and NS5A protein.
DAA can cure more than 95% of persons with HCV infection, thereby reducing 
the risk of death from cirrhosis and liver cancer.
Antiviral treatment is recommended for all patients with EHM.
Because of their not negligible rate of contraindications, important side effects, 
scarce tolerability, low compliance and adherence, length course of treatment, 
parenteral route of administration, and the insufficient rate of sustained virologi-
cal response (SVR) obtainable (not more than 60%), the interferon (IFN) based 
therapies for HCV hepatitis must be considered obsolete.
Moreover, IFN, with its immunological stimulating properties, could be 
contraindicated and possibly worsen or elicit some EHM (for example thyroid 
disfunction, autoimmune EHM). A caution attitude could be suggested also in MC, 
exacerbated in some cases treated with IFN alone (without glucocorticoids).
The antiviral drug ribavirin maintains a very marginal role in this context. 
Ribavirin common side effects are dermatologic and require caution if used in 
cutaneous EHM of HCV hepatitis.
DAA-based, IFN-free regimens should be considered the standard antiviral 
therapeutic approach in HCV-related EHM [21].
At the present, DAA-based, IFN-free regimens should be used following the 
recommendations for individuals with HCV mono-infection in the current interna-
tional guidelines.
Detailed assessment of drug–drug interactions is crucial since some medications 
are contraindicated or not recommended during DAA therapy [22, 23].
The vast majority of studies on the use of antiviral therapies in EHM - HCV 
diseases have been carried out in patients with MC vasculitis, which is considered 
the prototype of systemic autoimmune disease associated with HCV, both for 
their frequency and potential life-threatening involvement. All reported studies 
show that vasculitic manifestations largely improve after antiviral treatment (even 
in patients with partial virological responses) and often disappear, especially in 
patients with SVR.
Treatment of low-grade lymphomas only with DAAs antiviral therapies may be 




IFN-free antiviral regimens might be less effective than IFN-containing regi-
mens in some patients with B cell lymphoma, possibly due to the lack of additional 
anti-proliferative activity of IFN, while the association of rituximab with DAA 
regimens could be more effective than isolated antiviral therapies.
At the present there is little data on the response of other EHM to DAAs antiviral 
therapies for HCV hepatitis.
13.2 Non antiviral treatment of HCV-extrahepatic manifestations
Non-antiviral therapeutic approaches should be evaluated according to the type 
of EHM and the severity of the clinical presentation. The non-antiviral therapeutic 
approaches mainly used in EHM patients include glucocorticosteroids, immunosup-
pressant agents, plasma exchange and biological therapies.
Non-antiviral therapeutic approaches are recommended for moderate and, 
especially, for severe organ-specific involvements. Patients with moderate to severe 
vasculitic manifestations may be treated with short-term glucocorticoid regimens to 
control inflammation rapidly. Regimens of methylprednisolone (0.5–1.0 g/day) for 
three days followed by prednisone (not exceeding 1 mg/kg/day) may be appropriate 
in the setting of skin ulceration, sensorimotor neuropathy, glomerulonephritis, and 
other severe vasculitic manifestations.
For aggressive B cell NHL, the therapy remains based on immunochemotherapy 
with anthracycline-containing regimens in combination with rituximab as in HCV-
negative patients.
Plasma exchange may be added to other therapies, especially in patients with 
severe/life-threatening cryoglobulinaemic vasculitis. Such intervention is useful 
in patients with immediately life-threatening involvements and for those with 
hyperviscosity syndrome. Apheresis techniques should always be used as a comple-
mentary therapy in combination with other strategies (antiviral therapies, B cell 
depleting agents).
B cell depleting agents may currently be considered to be the best biological 
target option for patients with the more severe EHM, always with a reasonable 
individualized assessment of the benefits and risks. The most promising non-
antiviral therapeutic approach to HCV-related cryoglobulinemia is rituximab.
The use of antiviral therapies in combination with immunosuppressant/
biological agents should normally be made sequentially (first, use immunosup-
pressant/biological agents and, once the major end-organ effects have been 
controlled, use antiviral therapy), or concomitantly. It seems reasonable to carry 
out the combination on a case by-case basis [21].
The orally active thrombopoietin-receptor agonist elthrombopag may be used in 
severe thrombocytopenic HCV patients.
Appropriate local and systemic treatments are needed for cutaneous and ocular 
EHM of HCV (see above 10.) [18, 20].
14.  Prevention of extrahepatic manifestations treating HCV hepatitis 
with DAAs
In a large population study, it was found that successful DAA treatment resulting 
in SVR was associated with significant reductions in the future risk of several EHM 
of HCV, including MC, glomerulonephritis and LP but not NHL or diabetes. The 
magnitude of risk reductions ranged between 0.23 and 0.61.
SVR was associated with a reduction in risk of PCT, but it was only marginally 
statistically significant [24].
13
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15. Conclusions
Chronic HCV infection can cause significant EHM and should be considered as a 
systemic disease rather than a disease affecting only the liver.
EHM of HCV can affect virtually every organ via a variety of mechanisms.
It is important to emphasize that the severity of these disorders does not neces-
sarily correlate with the severity of hepatic disease.
Some investigations have shown that therapy of chronic HCV infection can 
result in resolution or improvement of extrahepatic diseases linked to HCV and 
even prevent their onset.
Awareness on the part of the clinician is necessary to recognize these numerous 
and heterogeneous pathological conditions. This in turn can lead to appropriate 
screening, early treatment and improved outcomes [4, 6].
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